What are you searching for?

Sign in
Online Exclusives

Investments in Lyophilization & Global API Manufacturing Market

API manufacturing market is expected to reach $250.7 billion in 2026 at a CAGR of 6.4%

By: Kristin Brooks

Managing Editor, Contract Pharma

According to ‘Pharmaceutical API Manufacturing Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026’  by The Business Research Company, the pharmaceutical API manufacturing market size is expected to grow from $179.1 billion in 2021 to $195.3 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%.1 Growth in the market is mainly attributed to companies resuming operations following the impacts of COVID-19. According to TBRC’s pharmaceutical API manufacturing market research the market is expected to reach $250.7 billion in 2026 at a CAGR of 6.4%, driven by an aging population.1
 
Active Pharmaceutical Ingredient (API) is any substance or mixture of substances intended to be used in the manufacture of a drug product and that becomes an active ingredient of the drug. APIs are intended to cause pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.
 

API Manufacturing & Lyophilization

Companies in API pharmaceutical manufacturing industry use technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in lyophilization. Also known as freeze drying, lyophilization is a means of stabilizing wet substances by freezing them, then evaporating the resulting ice, to leave a substantially dry, porous residue which has the same size and shape of the original frozen mass.

Industry Investments in Lyophilization Capabilities and Capacity

Berkshire Sterile Manufacturing (BSM), a sterile filling contract manufacturer located in Lee, MA, has recently added formulation, lyophilization, and method development capabilities to its drug development services.
 
For clients looking to enhance their drug product stability through freeze-drying, BSM can develop their lyophilization formulation, lyo cycles based on thermal properties, and scale-up the lyo process when the client moves on in their clinical trials or to commercialization. Read More

LSNE Contract Manufacturing, a global contract development and manufacturing organization (CDMO), has doubled its sterile drug product lyophilization capacity at its Madison, WI parenteral manufacturing facility, with the installation of a new lyophilizer. The Madison capacity increase is one step in a company-wide lyophilization expansion plan adding capacity to all existing facilities.
 
“In response to our clients’ needs, we have expanded our lyophilization capacity,” said Doug Craig, site head at LSNE-Madison. “There continues to be an uptick in their demand for lyophilization and we accelerated our plans to add capacity to be ready this month.” Read More 
 
Argonaut Manufacturing Services, a contract manufacturing organization (CMO) serving the life sciences, molecular diagnostics, and biopharma industries, is expanding its cGMP facilities in the Greater San Diego area of Carlsbad, CA. This will bring Argonaut’s manufacturing space to over 100,000 square feet and enable Argonaut to accommodate the changing dynamics of its business and the Life Science industry.
 
The new facility will be equipped with upgrades in additional automation to Argonaut’s existing formulation, fill and finish infrastructure. It will also be home to their new National Lyophilization Center dedicated to solving the ambient stability needs of Point of Care tests globally. Read More
 
References: 
1. https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics